LONGER-TERM FOLLOW-UP OF A PHASE 1 STUDY OF PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) LEUKEMIAS

被引：0
|
作者：
Cortes, J. [1 ]
Talpaz, M. [2 ]
Kantarjian, H. M. [1 ]
Shah, N. P. [3 ]
Bixby, D. [2 ]
Flinn, I. W. [4 ]
O'Hare, T. [5 ]
Hu, S. [6 ]
Rivera, V. [6 ]
Clackson, T. [6 ]
Turner, C. [6 ]
Haluska, F. [6 ]
Druker, B. J. [7 ]
Deininger, M. W. [5 ]
Mauro, M. J. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Univ Calif San Francisco, San Francisco, CA 94143 USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[6] ARIAD Pharmaceut Inc, Cambridge, MA USA
[7] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P895
引用
收藏
页码：335 / 335
页数：1
相关论文
共 50 条
  • [31] Long-Term Anti-Leukemic Activity of Ponatinib in Patients with Philadelphia Chromosome-Positive Leukemia: Updated Results from an Ongoing Phase 1 Study
    Deininger, Michael W.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Shah, Neil
    Bixby, Dale
    Mauro, Michael J.
    Flinn, Ian W.
    O'Hare, Thomas
    Hu, Simin
    Dorer, David J.
    Rivera, Victor M.
    Clackson, Tim
    Turner, Christopher D.
    Haluska, Frank G.
    Druker, Brian J.
    Talpaz, Moshe
    BLOOD, 2012, 120 (21)
  • [32] Hematologic safety data of single-agent ponatinib from a phase I and phase II trial in Philadelphia chromosome-positive (Ph plus ) CML/ALL patients.
    Greer, Devon M.
    Liewer, Susanna
    Akhtari, Mojtaba
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [33] Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results
    Kantarjian, Hagop
    Short, Nicholas J.
    Jain, Nitin
    Sasaki, Koji
    Huang, Xuelin
    Haddad, Fadi G.
    Khouri, Issa
    DiNardo, Courtney D.
    Pemmaraju, Naveen
    Wierda, William
    Garcia-Manero, Guillermo
    Kebriaei, Partow
    Garris, Rebecca
    Loghavi, Sanam
    Jorgensen, Jeffrey
    Kwari, Monica
    O'Brien, Susan
    Ravandi, Farhad
    Jabbour, Elias
    AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) : 493 - 501
  • [34] Hyper-CVAD Plus Ponatinib as Frontline Therapy in Philadelphia Chromosome-Positive (Ph plus ) Acute Lymphoblastic Leukemia (ALL): Updated Results of a Phase II Trial
    Maiti, Abhishek
    Kantarjian, Hagop
    Ravandi, Farhad
    Short, Nicholas
    Daver, Naval
    Pemmaraju, Naveen
    Thomas, Deborah
    Yilmaz, Musa
    Kadia, Tapan
    Sasaki, Koji
    Garris, Rebecca
    Garcia-Manero, Guillermo
    DiNardo, Courtney
    Konopleva, Marina
    Estrov, Zeev
    Jain, Nitin
    Weirda, William
    Jeanis, Vicky
    Cortes, Jorge
    O'Brien, Susan
    Jabbour, Elias
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 : S257 - S258
  • [35] PHASE II STUDY OF COMBINATION OF HYPERCVAD WITH PONATINIB IN FRONT LINE THERAPY OF PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME (PH) POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Jabbour, E.
    Kantarjian, H.
    Thomas, D.
    Ravandi, F.
    Cortes, J.
    Hoehn, D.
    Pemmaraju, N.
    Kadia, T.
    Garris, R.
    Garcia-Manero, G.
    Borthakur, G.
    Wierda, W.
    O'Brien, S.
    HAEMATOLOGICA, 2014, 99 : 258 - 259
  • [36] Phase II Study of Combination of Hypercvad with Ponatinib in Front Line Therapy of Patients (pts) with Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL)
    Jabbour, Elias
    Kantarjian, Hagop M.
    Thomas, Deborah A.
    Sasaki, Koji
    Ravandi, Farhad
    Cortes, Jorge E.
    Pemmaraju, Naveen
    Kadia, Tapan
    Garris, Rebecca
    Garcia-Manero, Guillermo
    Borthakur, Gautam
    Wierda, William G.
    O'Brien, Susan
    BLOOD, 2014, 124 (21)
  • [37] A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph plus ALL).
    Short, Nicholas James
    Kantarjian, Hagop M.
    Konopleva, Marina
    Bravo, Guillermo Montalban
    Ravandi, Farhad
    Jain, Nitin
    Kadia, Tapan M.
    Valero, Yesid Alvarado
    Chien, Kelly Sharon
    Daver, Naval Guastad
    Macaron, Walid
    Sasaki, Koji
    Thankachan, Jennifer
    Delumpa, Ricardo
    Mayor, Ejiroghene
    Deen, Wuliamatu
    Loiselle, Christopher
    Kwari, Monica
    Garris, Rebecca
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [38] Long-term follow-up of patients with Philadelphia chromosome-positive ALL followed by autologous BMT with ex vivo purging.
    Mizuta, S
    Kohno, A
    Morishita, Y
    Morishima, Y
    Saito, H
    BLOOD, 2000, 96 (11) : 426A - 426A
  • [39] Propensity score analysis: Frontline therapy with hyper-CVAD (HCVAD) plus ponatinib vs. HCVAD plus dasatinib in patients (pts) with Philadelphia chromosome-positive (Ph plus ) acute lymphoblastic leukemia (ALL).
    Sasaki, Koji
    Kantarjian, Hagop M.
    Ravandi, Farhad
    Thomas, Deborah A.
    Daver, Naval Guastad
    Kadia, Tapan M.
    Konopleva, Marina
    Jain, Nitin
    Short, Nicholas James
    Issa, Ghayas C.
    Jeanis, Vicky
    Moore, H. Gal
    Garris, Rebecca S.
    Garcia-Manero, Guillermo
    Cortes, Jorge E.
    O'Brien, Susan Mary
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [40] Ponatinib in Pediatric Patients with Philadelphia Chromosome-Positive Leukemia - Japanese Pediatric Leukemia/Lymphoma Study Group
    Kodama, Yuichi
    Sato, Atsushi
    Kato, Keisuke
    Kato, Motohiro
    Kawasaki, Hirohide
    Sakaguchi, Hirotoshi
    Hiramatsu, Hidefumi
    Kato, Itaru
    Taga, Takashi
    Shimada, Hiroyuki
    PEDIATRIC BLOOD & CANCER, 2020, 67
12345